Floatz logo

FLUOROURACILUM

Colorectal Adenocarcinoma

Centre Hospitalier Universitaire DijonSmall moleculePhase 3Active
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
59/ 100
Competitive Position
73/ 100

Competitive context

66 Active assets in the Colorectal Adenocarcinoma cohort.

Asset / SponsorPhaseRating
Regorafenib
City of Hope Medical Center
Phase 2BB
Trifluridine
Centre Hospitalier Universitaire Dijon
Phase 3BB
Balstilimab
City of Hope Medical Center
Phase 2BB
Botensilimab
City of Hope Medical Center
Phase 2BB
Cetuximab
Bayer
Phase 2BB

View all 50 →

Same molecule, other indications

FLUOROURACILUM is also rated in:

colon carcinomaDormant
A
Indicative ·
82 / 100
View asset →
Unresectable or Metastatic Colorectal CancerDormant
BBB
Indicative ·
79 / 100
View asset →
exocrine pancreatic carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →